HR2484

HR2484, the "Seniors’ Access to Critical Medications Act of 2025," creates a specific exception to the Stark Law (physician self-referral prohibition) for certain outpatient prescription drugs covered under Medicare Part D. This exception applies from January 1, 2026, to December 31, 2030. Physicians can now dispense these drugs directly to patients with whom they have an ongoing relationship, provided the patient had a face-to-face encounter within the prior year. This directly enables physician practices to capture revenue from drug dispensing that was previously prohibited, shifting a portion of the prescription drug market from traditional pharmacies to physician offices. The money trail shifts revenue from retail pharmacies to physician practices. While the bill does not appropriate new funds, it reallocates existing Medicare Part D spending. Physician practices will now bill for dispensed medications, adding a new revenue stream to their existing service offerings. This directly impacts the business models of large pharmacy chains and pharmacy benefit managers (PBMs) by introducing a new competitor: the prescribing physician. The bill's temporary nature (ending 2030) creates an incentive for physician groups to quickly integrate dispensing services. Historically, efforts to modify the Stark Law have been contentious due to concerns about conflicts of interest. However, specific carve-outs for certain services have occurred. For example, in 2009, the Affordable Care Act included provisions that allowed for certain exceptions related to accountable care organizations, which led to some consolidation in healthcare provider networks. While not directly comparable in scope, the market reaction to such changes typically involves a re-evaluation of revenue streams for affected entities. When the Centers for Medicare & Medicaid Services (CMS) issued a final rule in 2020 to modernize Stark Law exceptions, it aimed to reduce regulatory burden and facilitate value-based care. While no direct stock price surge was attributed solely to this, it generally supported integrated care models, which this bill further enables for drug dispensing. Specific winners include physician practices and potentially integrated healthcare systems that employ physicians, as they gain a new revenue stream. Losers are traditional retail pharmacies and pharmacy benefit managers (PBMs). Companies like CVS Health ($CVS), Walgreens Boots Alliance, and potentially Amazon Pharmacy ($AMZN) will face increased competition for outpatient prescription drug dispensing. Healthcare insurers with integrated PBMs, such as UnitedHealth Group ($UNH) and Cigna ($CI), may see a slight shift in their PBM revenue streams as more drugs are dispensed directly by physicians, although the overall impact on their PBM business requires further analysis of the specific drug types covered by the exception. The bill's passage through committee with a 38-7 vote indicates strong bipartisan support, suggesting a high likelihood of becoming law. Next, the bill moves to the full House for a vote. If passed, it proceeds to the Senate. Given the strong committee vote, the timeline for potential enactment is within the current legislative session, with the exception becoming effective on January 1, 2026. Companies in the retail pharmacy and PBM sectors will need to adjust their strategies to account for this new competitive landscape by early 2026.